Transfusion-dependent Anemia Clinical Trial
Official title:
Prediction of Transfusion-Associated Complications
Currently, about 350000 red blood cell concentrates are produced from blood donations in Austria every year. In addition to the main effect of replacing lost blood, red blood cell concentrates also have many undesirable effects - from blood group compatibilities, which are easily avoidable due to care, to storage-related side effects, to mostly intensive care problems as a result of massive transfusions, to system-wide effects such as TRALI, TACO and TRIM. Before being administered to patients, red blood cell concentrates undergo an extensive quality assurance process in which a large number of parameters are collected. Prior to use on patients, for example, bedside tests and tests for further incompatibilities with a blood sample from the intended patient are performed. With the implementation of Patient Blood Management (PBM) in recent years, the use of red cell concentrates has become more targeted - the number of transfusions is decreasing in most developed countries. However, it is still possible to suffer transfusion-related adverse events (TRAE). Thus, active research activity to reduce these TRAEs continues to be called for. To date, however, it is not known which patients experience transfusion-related adverse events. Despite the broad measures of hemovigilance and pre-transfusion testing, it is still not possible to predict which individual patient will respond to a transfusion with a typical adverse event such as hypotension, hemolysis, renal failure, or TRALI. It seems understandable that characteristics of the patient as well as characteristics of the administered unit could play a role for this. In particular, it is conceivable that a combination of characteristics of the blood unit and characteristics of the patient could determine a complication in the course of administration. For this reason, it seems attractive to use artificial intelligence and machine learning methods to predict any complications.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02435212 -
Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
|
Phase 2 | |
| Recruiting |
NCT05924100 -
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
|
Phase 2 | |
| Completed |
NCT04303910 -
An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty
|
||
| Terminated |
NCT03643042 -
Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome
|
N/A | |
| Completed |
NCT04856618 -
Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
|
||
| Recruiting |
NCT05462548 -
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
|
Phase 4 | |
| Completed |
NCT04155021 -
Knowledge and Attitude in Perioperative Erythrocyte Transfusion in Medical Personnel in Siriraj Hospital
|
||
| Active, not recruiting |
NCT05739097 -
Prospective Study on Feto-maternal outcoMe In aNemIc womEn
|
||
| Completed |
NCT05203016 -
Complications Associated With Intraoperative Hypothermia.
|
||
| Recruiting |
NCT03369210 -
Liberal Transfusion Strategy in Elderly Patients
|
Phase 3 |